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Lung flute improves symptoms and health status
in COPD with chronic bronchitis: A 26 week
randomized controlled trial
Sanjay Sethi1,2*, Jingjing Yin2 and Pamela K Anderson2

Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by mucus hypersecretion that
contributes to disease related morbidity and is associated with increased mortality. The Lung Flute® is a new
respiratory device that produces a low frequency acoustic wave with moderately vigorous exhalation to increase
mucus clearance. We hypothesized that the Lung Flute, used on a twice daily basis will provide clinical benefit to
patients with COPD with chronic bronchitis.
Methods: We performed a 26 week randomized, non-intervention controlled, single center, open label trial in 69
patients with COPD and Chronic Bronchitis. The primary endpoint was change in respiratory symptoms measured
with the Chronic COPD Questionnaire (CCQ). Secondary endpoints included health status, assessed by the St. George
Respiratory questionnaire (SGRQ), BODE (Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity)
index score and exacerbation frequency.
Results: While the control patients did not demonstrate any significant changes in the primary endpoint (CCQ change
at 26 weeks of +0.01, p = 0.8), a trend (p = 0.08) to decrease (improvement) in the CCQ (-0.23 at 26 weeks) was seen
with the Lung Flute. Furthermore, a significant improvement in the symptom domain of the CCQ was seen only with
the lung flute (-0.42, p = 0.004). Health status (SGRQ) improvement, was also only seen with the Lung Flute (-3.23, p = 0.03).
The BODE score increased in the control group (3.31 at baseline, 4.14 at 26 weeks), however it remained stable in the Lung
Flute arm (3.16 at baseline and 26 weeks), with the changes from baseline being significantly different between the 2 arms
(p = 0.01). There was a trend for less exacerbations in the Lung Flute group (p = 0.07). Adverse effects were minor, with only
1 patient discontinuing treatment because of lack of efficacy. Serious adverse effects seen were all determined to be
unrelated to the device use.
Conclusions: The Lung Flute is a safe and effective treatment in COPD with chronic bronchitis, providing a wide array of
benefits.
ClinicalTrials.gov Identifier: NCT01186822
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Background
Mucus hypersecretion and impaired mucociliary clearance is prevalent in many patients with COPD, and contributes significantly to the morbidity and mortality of
this disease [1,2]. In spite of the need for efficacious,
convenient and safe treatment for mucus hypersecretion,
current choices are few with limited data to support
their efficacy in COPD [3,4]. The Lung Flute is a new
small self-powered audio device that has been classified
by the Food and Drug Administration (FDA) to the
family of Oscillatory Positive Expiratory Pressure (OPEP)
devices, which includes the Flutter® and the Acapella®
[5,6]. However, unlike traditional OPEP devices that use
oscillatory back pressure, the Lung Flute has a unique
mechanism of action based on acoustic energy. When
blown in to with an exhalation vigorous enough to make
the reed oscillate, the Lung Flute generates a sound wave
of 16 to 22 Hz with an output of 110 to 115 dB using
2.5 cms H2O of pressure. This sound wave has the ability
to travel down the tracheobronchial tree and vibrate
tracheobronchial secretions. This vibration enhances
mucociliary clearance of the lower respiratory tract
thereby resulting in the induction of sputum. This functionality of the Lung Flute has been applied to sputum
induction for diagnostic testing and for the enhancement of mucus clearance from the lower airways (Data
on file, Medical Acoustics) [7,8]. The Lung Flute is
currently FDA approved and available for patient use
by a health care provider prescription for both these
purposes.
Therapeutic use of the Lung Flute was initially tested
in a trial that as designed to meet regulatory requirements. In a FDA 510(k) non-inferiority study, the Lung
Flute was compared to a FDA cleared OPEP device
(Acapella®) in a eight-week, randomized, controlled, two
arm open-label parallel study in 40 COPD patients with
chronic bronchitis. Both devices improved COPD symptoms and disease specific health status, with trends favoring the Lung Flute (Data on file, Medical Acoustics).
We wanted to confirm and explore further the therapeutic use of the Lung Flute in COPD in a longer trial
and compare it to usual care. This report describes the
results of such a 26 week study where patients were randomized to the Lung Flute or usual care. The primary
endpoint was COPD symptoms as assessed by the
Chronic COPD Questionnaire (CCQ) [9]. Secondary
endpoints assessed included spirometric lung function,
exercise tolerance, exacerbations and health status.
Methods
Study design

This was a 26-week, two arm, open label, parallel groups
study. Subjects were randomized to the Lung Flute or
usual care. The clinical trial registration number of this
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trial is NCT01186822. The study was approved by the
Human Studies subcommittee for the Department of
Veterans Affairs (VA) Western New York Healthcare
system. All participants provided written informed consent prior to any study procedures.

Subjects

We had planned to enroll 80 subjects (see power analysis
below) with COPD with chronic bronchitis at a single
center (Buffalo VA Medical Center). Inclusion criteria
were: a) between 30-80 yrs of age, b) presence of airflow
obstruction by spirometry post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity
(FVC) ratio <70% and FEV1 < 80% predicted, GOLD Stage
2-4), c) presence of chronic bronchitis, i.e. cough productive of sputum on most days of the week, d) current
smoker or ex-smoker with at least 10 pack yrs of smoking
history, e) able to vibrate the reed of the Lung Flute® using
the standard therapeutic maneuver. Exclusion criteria
were a) exacerbation of COPD within 4 weeks prior to
enrollment, b) predominant asthma and bronchiectasis by
clinical assessment, c) pregnant or nursing women d)
chronic use of a mucolytic medication.

Procedures

The study consisted of a screening and randomization
visit and then on treatment clinic visits at 2, 14 and
26 weeks. All visits were performed on an outpatient
basis. In addition, standardized telephonic assessments
were made at 8 and 20 weeks. Participants who met the
inclusion/exclusion criteria were randomized to either
the Lung Flute or usual care on a 1:1 allocation basis.
Randomization was by predetermined random sequence
generated independently and kept in sealed envelopes
until the time of randomization.
At baseline prior to randomization, symptoms were
measured with the CCQ and health status with the St.
George’s respiratory questionnaire (SGRQ) [9-11]. Lung
function was assessed by post-bronchodilator spirometry,
exercise capacity by the six minute walk test, dyspnea by
the measurement of the modified Medical Research
Council (mMRC) score and body mass by calculating
the body mass index (BMI). These measurements were
used to calculate the BODE index as has been described
earlier [12].
At each subsequent clinic visit, all the above evaluations were repeated and review of concomitant medication, compliance assessment, adverse event surveillance
and exacerbation history were performed. The telephone
calls consisted of a standardized assessment of concomitant medication, compliance assessment, adverse event
surveillance and exacerbation history.
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Intervention

The Lung Flute arm participants were instructed to blow
twice in to the Lung Flute device vigorously enough to
make the reed oscillate, followed by 5 normal breaths.
This was repeated 10 times, followed by 3 huff coughs
to complete 1 cycle. Two such cycles were recommended
twice a day. One of these cycles was performed under
supervision of the study personnel at the time of enrollment and at each subsequent study visit. Baseline COPD
medication regimen was continued in all participants,
although the primary physicians of the participants could
make medically necessary changes. Chest physical therapy,
additional breathing exercises and formal pulmonary rehabilitation programs were not prescribed to any of the
participants during the study.
Endpoints

The primary endpoint of this study was comparison of
the change in COPD symptoms assessed by the CCQ
questionnaire between the intervention and control
group at 26 weeks. Secondary endpoints included comparison of the changes in SGRQ score, spirometric lung
function, BODE index, and exacerbation frequency at
26 weeks between the 2 arms.
Data analysis

All analyses were performed in an intention to treat
(ITT) manner. Subject demographics were compared
with t tests and chi square analyses as appropriate. For

Figure 1 Flow chart of participants in the study.
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normally distributed outcomes (e.g. CCQ and SGRQ
scores), paired t-test was applied to compare week 26
(week 14/ week 2) to baseline for the two arms, respectively. Also 2-sample independent t-test is used to compare the two arms at baseline, and to compare the
changes of week 26 (week 14/ week 2) from baseline in
the two arms. For outcomes which failed the normality
test (e.g. BODE score), Wilcoxon signed ranks test is
applied to compare week 26 (week 14/ week 2) to baseline for the two arms, respectively. Also Wilcoxon-Mann
Whitney test is used to compare the two arms at baseline, and to compare the changes of week 26 (week 14/
week 2) from baseline in the two arms. Fisher’s exact test
is applied to compare the exacerbation frequencies of
the two arms. A p < 0.05 was considered significant.
Missing data were imputed by carrying forward the last
observation.
Power analysis

In order to determine sample size, we used the primary
outcome of the CCQ score. In previous 8 week studies
with Lung Flute, an average improvement of 0.4 (S.D. of
0.64) in the CCQ score has been seen with this device.
We assumed that the control group will have a change
of .05 in the CCQ score. With an alpha = 0.1 (one sided
t test) and power = 0.8 and a 1:1 allocation, a total sample size of 76 was required. Allowing for a 5% drop-out
rate, a total of 80 patients were to be included in this
study.
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Table 1 Subject demographics
Characteristic

Lung Flute (n = 33)

Control (n = 36)

p value

Age

68.88 ± 1.49

67.97 ± 1.29

0.58
0.89

Gender

Race

Male = 29

Male = 32

Female = 4

Female = 4

Caucasian = 30

Caucasian = 33

African-American = 3

African-American = 3

0.91

Smoking history ( pack yrs)

62.16 ± 7.13

60.26 ± 4.60

0.82

Smoking status

Current = 13

Current = 12

0.60

Ex = 20

Ex = 24

FEV1 (liters)

1.71 ± 0.13

1.53 ± 0.11

0.30

FEV1% predicted

51.19 ± 2.98

49.13 ± 3.18

0.64

0.31

Baseline COPD medications N (%)
- LAMA + LABA/ICS

11 (33.3)

19 (52.8)

- LABA/ICS

6 (18.2)

3 (8.3)

- LAMA/LABA

2 (6.1)

1 (2.8)

- LAMA

3 (9.0)

3 (8.3)

- LABA

1 (3.0)

3 (8.3)

- SAMA/SABA

5 (15.2)

6 (16.7)

- SABA/none

5 (15.2)

1 (2.8)

LAMA = long actiing anti-muscarinic agent (e.g. tiotropium), LABA = long acting β agonist (e.g. formoterol), ICS = inhaled corticosteroid (e.g. budesonide),
SAMA = short acting anti-muscarinic agent (e.g. ipratropium), SABA = short acting β agonist (e.g. albuterol).

Results
Participants

We screened a total of 91 patients and 69 patients were
enrolled (Figure 1). The most common reason for screen
failure was the absence of at least moderate airflow obstruction. Of the enrolled patients, 33 were randomized to Lung
Flute, while 36 to control arm. Of the enrolled participants
59 completed the study, 26 of the 33 participants in
the Lung Flute arm and 33 of the 36 participants in the
control arm. None of the early termination/withdrawals
were related to the device, except for one patient who

withdrew consent at 2 weeks because of perceived
lack of efficacy.
Baseline clinical characteristics of the participants
randomized in to the study are described in Table 1.
There were no statistically significant differences in the
demographics, smoke exposure history and lung function
between the subjects enrolled in the two arms.
COPD symptoms (CCQ)

The CCQ is an objective validated tool to assess COPD
symptoms [9]. It consists of 10 items, divided into 3

Figure 2 Change in the CCQ score during the study in the two arms. The p values are for the change from baseline within each group.
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Table 2 Change in CCQ total and domain scores from
baseline at 2, 12 and 26 weeks for the Lung Flute group

Table 3 Change in CCQ total and domain scores from
baseline at 2, 12 and 26 weeks for the control group

Lung Flute group

Control group

Score

2 weeks

14 weeks

26 weeks

Score

2 weeks

14 weeks

26 weeks

Total

-0.24#

-0.21

-0.23##

Total

-0.06

-0.05

+0.01

Symptom domain

-0.30*

-0.27**

-0.42***

Symptom domain

-0.21

-0.14

-0.11

Mental domain

-0.32

-0.17

-0.05

Mental domain

0.0

0.0

0.0

Function domain

-0.14

-0.17

-0.12

Function domain

+0.05

+0.02

+0.14

#

p = 0.02, ##p = 0.08, *p = 0.003, **p = 0.06, ***p = 0.004.
P values <0.10 are shown.

P values <0.10 are shown.

Health status (SGRQ)

domains: symptoms (4 items), functional state (4 items)
and mental state (2 items). Each question can be answered
from 0 = best, 6 = worst, and the CCQ score is derived as
the average of the individual question scores, with a range
of 0-10. A reduction in the CCQ score denotes a reduction
in COPD symptoms. There was no difference in the baseline CCQ score in the 2 groups (p = 0.81). The CCQ score
at 26 weeks in the control group had increased (worsened)
by 0.01 points (p = ns). In the Lung Flute group, a decrease
(improvement) of 0.23 points in the CCQ score was seen at
26 weeks (p = 0.08). When intermediate timepoints were
examined, the change in CCQ with the Lung Flute was
evident at 2 weeks (0.24 points, p = 0.02) and sustained at
14 weeks (0.21 points, p = 0.11) while the changes in the
control group were small and non-significant (Figure 2).
When changes in the domain scores were examined in
the 2 arms, the symptoms domain showed the largest
responses to the lung flute, with a 0.42 point improvement
seen at 26 weeks (p = 0.004), as well as significant
improvements at 2 and 14 weeks (Tables 2 and 3).
The items in this domain quantify shortness of
breath at rest, shortness of breath with physical activity,
cough and phlegm production respectively. Changes in
function and mental domains with the Lung Flute were
not consistent or statistically significant.

SGRQ is a well validated, widely used health status
questionnaire specific for COPD [11]. A reduction in the
SGRQ score denotes an improvement in disease specific
health status or quality of life. There was no difference
in the baseline SGRQ score in the 2 groups (p = 0.22).
The Lung Flute arm showed a progressive improvement
in health status, with a significant decrease of 3.23
points seen by week 26 (p = 0.03) (Figure 3). In contrast,
the decrease in SGRQ of 1.85 points at week 26 with
usual care was non-significant. Consistent with the CCQ
observations, the largest and most consistent changes
with the Lung Flute were seen in the symptoms domain,
with minimal changes in activity and only a 26 week
change in the impact domain (Tables 4 and 5). Usual
care was not associated with significant improvement in
any SGRQ domain.
BODE score and its components

Over the 26 weeks, BODE score in the Lung Flute arm
did not change from baseline, being 3.16 at baseline and
3.16 at 26 weeks. However, in the usual care arm, there
was a noticeable worsening in the BODE score, with an
increase from the baseline value of 3.31 to 4.14 at
26 weeks (p = 0.0006). When individual components of
the BODE score were examined, BMI and FEV1 did not

Figure 3 Change in the SGRQ score during the study in the two arms. The p values are for the change from baseline within each group.

Sethi et al. Clinical and Translational Medicine 2014, 3:29
http://www.clintransmed.com/content/3/1/29

Page 6 of 8

Table 4 Change in SGRQ total and domain scores at 2, 12
and 26 weeks for the Lung Flute group

Table 6 BODE scores and its components at 2, 12 and
26 weeks for the Lung Flute group

Lung Flute group

Lung Flute group

Score

2 weeks

14 weeks

26 weeks

Total

-1.52

-2.38

-3.23#

Symptom domain

-2.2

-4.1*

-3.6**

Impact domain

-2.25

-1.1

-3.37***

Activity domain

+0.59

-3.34

-1.18

P values <0.10 are shown.
#
p = 0.03, *p = 0.08, **p = 0.08, ***p = 0.09.

change significantly in either arm, however, deteriorations in mMRC and 6 minute walk distances were seen
only in the control arm (Tables 6 and 7).
Exacerbations

Six of the 33 patients in the Lung Flute group, while 14 of
36 patients in the control group experienced at least one
moderate to severe exacerbation, defined as an exacerbation
requiring outpatient treatment with antibiotics and/or
corticosteroids or requiring hospitalization (p = 0.07).
Figure 4 illustrates the timing of the first exacerbation
during the study in the 2 arms, and the probability of not
having an exacerbation favors the lung flute (p = 0.03).
Patient preference

When asked at the end of the study visit, 85% of the patients
that were randomized to the lung flute indicated that they
found the device to be efficacious and would like to continue using it as a regular part of their COPD care regimen.
Safety

There were two deaths in the Lung Flute group and
none in the control group. There were serious adverse
events in both groups, most commonly hospitalization
due to COPD or co-morbid conditions. None of the
deaths and serious adverse events were determined to be
related to Lung Flute use. One patient complained of increased cough with the Lung Flute. There were no study
withdrawals related to the adverse effects with the use of
the Lung Flute.
Table 5 Change in SGRQ total and domain scores at 2, 12
and 26 weeks for the control group

Parameter

Baseline

2 weeks

14 weeks

26 weeks

BODE

3.16 ±
0.49

3.13 ±
0.49

3.25 ±
0.48

3.16 ±
0.45

BMI

27.98 ±
1.19

27.57 ±
1.15

26.27 ±
1.03

26.12 ±
0.97

FEV1% predicted

51.19 ±
2.98

51.19 ±
3.38

50.36 ±
3.24

50.15 ±
3.10

mMRC score

1.48 ±
0.19

1.42 ±
0.20

1.36 ±
0.21

1.52 ±
0.21

6 minute walk
distance

353.03 ±
29.95

355.88 ±
32.05

355.63 ±
30.58

359.18 ±
29.19

P values <0.10 are shown.

Discussion
There is an unmet medical need for dealing with mucus
hypersecretion, impaired mucociliary clearance and secretion retention in COPD, with a paucity of treatments
that have demonstrated efficacy for these disorders.
Currently available mucolytics and expectorants are of
unproven efficacy in COPD, and the beneficial effects
of agents such as n-acetylcysteine and carbocisteine are
more likely related to their antioxidant effects rather
than their mucolytic effects [13,14]. Mechanical means
to improve mucus clearance in hypersecretory lung
conditions include Oscillatory PEP devices such as the
Acapella and Flutter, chest vibration and percussion
and breathing techniques. However, these have not
been tested systematically in stable COPD. This postmarketing study confirms the previous regulatory study
that the Lung Flute is efficacious in COPD with chronic
bronchitis in improving respiratory symptoms and health
status. The largest improvements were seen in symptom
domains of the CCQ and SGRQ. Furthermore, it confirms
the safety of this device in COPD with related adverse
effects being seldom seen.
Table 7 BODE scores and its components at 2, 12 and
26 weeks for the control group
Control group
Parameter

Baseline

2 weeks

14 weeks

26 weeks

BODE

3.31 ±
0.45

3.49 ±
0.50

3.54 ±
0.47

4.14 ±
0.51*

BMI

27.15 ±
0.74

27.10 ±
0.74

27.14 ±
0.73

26.91 ±
0.73

FEV1% predicted

49.13 ±
3.18

47.60 ±
3.31

46.82 ±
3.30***

47.16 ±
3.45

mMRC score

1.81 ±
0.15

1.81 ±
0.18

1.83 ±
0.19

2.22 ±
0.19**

6 minute walk
distance

364.20 ±
25.73

353.47 ±
28.35

358.21 ±
26.52

322.41 ±
29.78 ****

Control group
Score

2 weeks

14 weeks
#

26 weeks

Total

-1.71

-2.60

-1.85

Symptom domain

-3.6*

-1.3

-2.8

Impact domain

-1.88

-3.1

-1.9

Activity domain

-0.81

-3.36

-1.2

P values <0.10 are shown.
#
p = 0.07, *p = 0.06.

P values <0.10 are shown.
*p = 0.0006, **p = 0.01, ***p = 0.03, ****p = 0.007.
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Figure 4 Probability of not having an exacerbation during the study in the two arms (p = 0.03, Wilcoxon signed rank test).

In addition to the improvements in symptoms and
health status, several of the secondary endpoints also
demonstrated the benefit of the Lung Flute in COPD.
The Lung Flute appeared to stabilize the BODE score,
primarily through preventing the progressive decrement
in 6 minute walk distance and increase in dyspnea seen
in COPD. Furthermore, a trend to reduction of exacerbations was seen. These observations need to be confirmed in the future with studies that are of appropriate
size and duration to definitively assess treatment benefit
in these aspects of COPD.
The mechanism of action that results in clinical benefits of Lung Flute in COPD is presumed to be increased
mucocilary clearance of tracheobronchial secretions.
However, a limitation of this study was the absence of
direct measurement of mucociliary clearance. Other
limitations of this study include it being a single site
study of relatively small size, and the lack of blinding,
which is difficult in device studies. However, of note,
all endpoints in this study were either patient reported
outcomes (CCQ, SGRQ, mMRC) or were objective
measures (Spirometry, 6 minute walk distance). Subjective investigator assessments of treatment effects
were therefore avoided in this trial, minimizing bias.
Furthermore, the control group clearly showed either
no change or slight worsening in all these parameters
as expected.
We had planned to enroll 80 participants in the study
but a larger than expected screen failure rate and financial
and time constraints resulted in enrollment of smaller
number of 69 participants. The mean magnitude of improvement at 26 weeks in the CCQ with the Lung Flute
was also somewhat smaller in the current trial (-0.23) than
in the original registration 8 week trial (-0.40). These

factors likely explain why the CCQ improvement in the
Lung Flute group did not reach statistical significance.
However, the totality of the benefit seen in the various
other endpoints assessed does support the efficacy of the
Lung Flute in COPD with Chronic Bronchitis.

Conclusions
The cost of chronic care of COPD continues to grow with
expansion of the possible medication regimen that could
be used in these patients. Each additional medication also
places the patient at increased risk of adverse effects. Furthermore, none of the standard treatments, inhaled bronchodilators, inhaled corticosteroids or phosphodiestrase
inhibitors have demonstrated effects to improve mucociliary clearance in COPD. The Lung Flute therefore represents a welcome addition to our armamentarium for the
treatment of COPD because of its potential unique mechanism of action, low cost and safety.
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